AG
RYTM icon

Aperio Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Aperio Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$808K Buy
27,181
+1,672
+7% +$42.5K ﹤0.01% 1706
2020
Q3 		$553K Buy
25,509
+13,707
+116% +$314K ﹤0.01% 1763
2020
Q2 		$263K Buy
+11,802
New +$230K ﹤0.01% 2074
2019
Q3 		– Sell
-390
Closed -$9K – 2670
2019
Q2 		$9K Buy
+390
New +$9.85K ﹤0.01% 2799

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Aperio Group's RYTM Position: Q4 2020 in Review

Aperio Group increased its Rhythm Pharmaceuticals (RYTM) stake by 6.6% in Q4 2020, buying an estimated $42.5K and bringing the position to 27,181 shares worth $808K. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Aperio Group first reported a position in RYTM in Q2 2019 and has held it in 4 quarters since. 119 funds tracked by Wall St. Rank hold RYTM as of Q4 2020.

  • Aperio Group held 27,181 shares of Rhythm Pharmaceuticals worth $808K as of Q4 2020.
  • Aperio Group bought 1,672 Rhythm Pharmaceuticals shares in Q4 2020, an estimated $42.5K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1706 holding.
  • Aperio Group first reported a position in Rhythm Pharmaceuticals in Q2 2019 and has held it in 4 quarters since.
  • 119 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.